ANIP News and Press, ANI Pharmaceuticals Inc. From 11/01/21

ANI Pharmaceuticals ( NASDAQ: ANIP ) recently announced that it recorded $52.1 million net revenues for its third quarter of 2021. However, this was roughly one million dollars less than what they reported in the same quarter of the previous fiscal year. The stock is up...

Shares of Ani Pharmaceuticals (NASDAQ: ANIP) took flight on Monday morning. The maker of generic and branded drugs delivered both a positive earnings report and some good news on the regulatory front -- the FDA has approved its generic version of Acthar Gel. Investors hoping for a b...

ANI Pharmaceuticals, Inc. (ANIP) Q3 2021 Earnings Conference Call November 1, 2021 8:30 am ET Corporate Participants Lisa Wilson - Investor Relations Nikhil Lalwani - President and Chief Executive Officer Steve Carey - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymo...

Gainers: ABVC BioPharma (NASDAQ:ABVC) +250%, ANI Pharmaceuticals (NASDAQ:ANIP) +51%, Artelo Biosciences (NASDAQ:ARTL) +37%, Nutriband (NTRBW) +34%, Regencell Bioscience (NASDAQ:RGC) +15%. Losers: Centessa Pharmaceuticals (NASDAQ:CNTA) -19%, Mi...

ANI Pharmaceuticals (ANIP +46.1%) shares are sharply higher today after the company reported better than expected Q3 2021 earnings and was granted an expanded approval for its cortrophin gel. The company hit a 52-week high of $57.69 earlier in the morning. ANI also said its acquisition o...

After Alnylam Pharmaceuticals (NASDAQ:ANIP) suffered a loss of nearly 20% last week on the departure of company’s long-serving CEO John Maraganore, Oppenheimer has upgraded the stock expecting the shares to recover as the impact of the news wanes over time. The price tar...

ANI Pharmaceuticals (NASDAQ:ANIP): Q3 Non-GAAP EPS of $1.01 beats by $0.31; GAAP EPS of -$0.37 misses by $0.16. Revenue of $52.06M (-1.7% Y/Y) beats by $2.36M. Shares +5.40% PM. Press Release For further details see: ANI Pharmaceuticals EPS beats by $0.31, beats on revenue

The U.S. FDA has approved ANI Pharmaceuticals' (NASDAQ:ANIP) sNDA for Purified Cortrophin Gel for the treatment of certain chronic autoimmune disorders. The approval allows for the use of Cortrophin in conditions, including acute exacerbations of multiple sclerosis (MS) and rheumato...

-- Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted loss per share of ($0.37) -- -- Third quarter adjusted non-GAAP EBITDA of $16.6 million and adjusted non-GAAP diluted earnings per share of $1.01 -- -- FDA approves supplemental n...

-- Cortrophin Gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders -- -- Approval re-introduces much needed patient and physician choice into the U.S. repository corticotropin market -- -- Early Q1 ...